# Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia

> **NCT02098278** · PHASE2 · COMPLETED · sponsor: **Catabasis Pharmaceuticals** · enrollment: 13 (actual)

## Conditions studied

- Lipoprotein Lipase Deficiency, Familial
- Hyperlipoproteinemia Type I
- Chylomicronemia, Familial
- Hypertriglyceridemia

## Interventions

- **DRUG:** CAT-2003
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02098278
- **Lead sponsor:** Catabasis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2016-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02098278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02098278, "Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02098278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*